@brian_armstrong: Aging is arguably the root cause of most major diseases (loss of function in our cells). Four years ago, we made a bet …
Summary
Brian Armstrong announces that NewLimit has developed a prototype drug that reverses cellular aging in human cells, with a clinical trial scheduled for next year, and has raised $435M in Series C funding led by Founders Fund.
View Cached Full Text
Cached at: 06/03/26, 09:54 PM
Aging is arguably the root cause of most major diseases (loss of function in our cells). Four years ago, we made a bet that aging was treatable, and NewLimit was born.
NewLimit now has a prototype drug that reverses the age of some human cells (restores function they had when they were younger), and a clinical trial scheduled for next year (with more drug candidates in the pipeline).
Grateful to Founders Fund, Thrive, Greenoaks, and the rest of the investors for this latest round. @jacobkimmel and the team are just getting started.
NewLimit (@newlimit): Following breakthrough results, we’re bringing longevity medicine to human trials.
We’ve raised a $435M Series C led by @foundersfund to make it happen.
Reprogramming cell age has the potential to create more healthy years for everyone. We’re closer than ever to realizing it.
Similar Articles
Why “reprogramming” is the buzziest approach to reversing aging right now
A biotech company has dosed its first volunteer in a clinical trial for an experimental glaucoma treatment that uses cellular reprogramming to reverse age-related damage, part of a broader trend toward rejuvenation therapies.
Fast-tracking genetic leads to reverse cellular aging
DeepMind's Co-Scientist is helping biologists identify genetic factors that reverse cellular aging by mining literature and analyzing screening data, reducing analysis time from months to days.
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Life Biosciences has dosed its first patient with ER-100, a cellular rejuvenation therapy aiming to reverse age-related sight loss, in a first-ever human clinical trial approved by the FDA.
Roundtables: Longevity’s Next Frontier: “Reprogramming” Your Body
A subscriber-only roundtable discussion hosted by MIT Technology Review explores the frontier of longevity research, focusing on cellular reprogramming as a potential treatment to reverse aging.
Single dose of New Limit's cellular reprogramming therapy improves survival in alcohol liver damage mouse models over multiple months of repeated alcohol cycles
New Limit's cellular reprogramming therapy, delivered via mRNA in lipid nanoparticles, restores liver resilience and improves survival in aged mice subjected to repeated alcohol cycles, with human trials planned next year in Australia.